Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Zevalin Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
Growth witnessed during the historic period was primarily a consequence of the advancement of monoclonal antibody development, the expansion of nuclear medicine capabilities, an increase in the diagnosis of non-hodgkin lymphoma, the early clinical use of radiolabeled therapies, and improvements in oncology imaging technologies.
The anticipated expansion during the projection period is driven by greater funding for specific cancer treatments, a heightened need for customized cancer care, the enlargement of facilities for radioactive drugs, a prioritization of effective treatments with fewer side effects, and ongoing advancements in antibody-driven cancer therapies.
Key developments expected during this timeframe involve broader acceptance of focused radioimmunotherapy, wider application of precise cancer treatment methods, the expansion of lymphoma-specific treatment guidelines, improved integration of nuclear medicine facilities, and an increased emphasis on treatment specificity.
Get A Free Sample Report With In-Depth Market Insights:
Zevalin Market Growth Catalysts And Demand Drivers
The increasing occurrence of non-Hodgkin’s lymphoma is poised to boost the expansion of the zevalin market in the coming period. This type of lymphoma comprises various blood cancers originating in lymphocytes, affecting both the lymphatic and immune systems. Factors contributing to its prevalence include an aging demographic, heightened exposure to risk elements such as immunosuppression, alongside environmental factors and evolving lifestyles. Zevalin functions as a monoclonal antibody, specifically targeting CD20, a protein present on B-cells frequently impacted in non-Hodgkin’s lymphoma. It provides focused radiation to eliminate cancerous B-cells, leading to tumor reduction and a higher chance of remission. As an illustration, a January 2024 report from the American Cancer Society, Inc., a US-based nonprofit, identified non-Hodgkin lymphoma as one of the most common cancers in the United States, accounting for roughly 4% of all new cancer diagnoses. In 2024, an estimated 80,620 people are projected to receive this diagnosis, with 44,590 being males and 36,030 females. Consequently, the growing incidence of non-Hodgkin’s lymphoma is fueling the expansion of the zevalin market. The expansion of healthcare infrastructure is a key factor propelling the zevalin market’s growth moving forward. Healthcare infrastructure encompasses the facilities, operational frameworks, equipment, and personnel essential for delivering medical services. This expansion is influenced by an aging population, increasing demand for high-quality medical care, greater government funding and backing, and progress in medical technology. Improved healthcare infrastructure facilitates better access to sophisticated cancer treatments, elevating the importance of zevalin in cancer therapy, with its targeted radioimmunotherapy enhancing patient recovery within a more robust healthcare system. For example, data from May 2023, provided by the American Health Care Association, a US-based nonprofit, indicated that the United States possessed 6,129 hospitals, marking a 0.591% rise from 6,093 hospitals recorded in the preceding year. Thus, the development of healthcare infrastructure is fueling the expansion of the zevalin market.
Zevalin Market Segment Analysis And Revenue Potential
The zevalin market covered in this report is segmented –
1) By Indication: Relapsed Or Refractory Low-Grade Non-Hodgkin Lymphoma (NHL), Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)
2) By Formulation: In-111 Zevalin, Y-90 Zevalin
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Online Pharmacies
4) By End-User: Adult Patients, Geriatric Patients
Zevalin Market Key Players Shaping Industry Direction
Major companies operating in the zevalin market are Acrotech Biopharma Inc.
View The Full Zevalin Market Report:
Zevalin Market Regional Analysis And Leading Geography
North America was the largest region in the zevalin market in 2025. The regions covered in the zevalin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
